Enterprise Financial Services Corp Sells 18,763 Shares of Bristol-Myers Squibb (NYSE:BMY)

Enterprise Financial Services Corp reduced its position in Bristol-Myers Squibb (NYSE:BMYGet Rating) by 57.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,711 shares of the biopharmaceutical company’s stock after selling 18,763 shares during the quarter. Enterprise Financial Services Corp’s holdings in Bristol-Myers Squibb were worth $855,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BMY. Bell Investment Advisors Inc purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth about $29,000. Steward Financial Group LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth about $29,000. Horan Securities Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth about $29,000. Consolidated Planning Corp purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth about $34,000. Finally, Leverty Financial Group LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth about $37,000. 73.07% of the stock is currently owned by institutional investors.

BMY traded up $0.20 during trading on Wednesday, hitting $77.33. The stock had a trading volume of 294,167 shares, compared to its average volume of 15,010,080. The company has a market capitalization of $164.64 billion, a PE ratio of 27.35, a PEG ratio of 1.61 and a beta of 0.49. Bristol-Myers Squibb has a twelve month low of $53.22 and a twelve month high of $78.46. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.23 and a current ratio of 1.32. The stock has a 50 day simple moving average of $75.28 and a two-hundred day simple moving average of $67.32.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last posted its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.92 by $0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The business had revenue of $11.65 billion during the quarter, compared to the consensus estimate of $11.34 billion. During the same period in the previous year, the firm posted $1.74 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 7.57 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 2nd. Stockholders of record on Friday, April 1st were paid a dividend of $0.54 per share. The ex-dividend date was Thursday, March 31st. This represents a $2.16 annualized dividend and a dividend yield of 2.79%. Bristol-Myers Squibb’s payout ratio is currently 76.60%.

In related news, CEO Giovanni Caforio sold 30,000 shares of the firm’s stock in a transaction on Thursday, February 24th. The shares were sold at an average price of $67.00, for a total transaction of $2,010,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Rupert Vessey sold 74,559 shares of the firm’s stock in a transaction on Wednesday, March 16th. The stock was sold at an average price of $69.25, for a total transaction of $5,163,210.75. The disclosure for this sale can be found here. Insiders have sold 165,668 shares of company stock valued at $11,459,888 over the last quarter. Insiders own 0.09% of the company’s stock.

A number of analysts recently weighed in on BMY shares. BMO Capital Markets increased their price objective on shares of Bristol-Myers Squibb from $87.00 to $92.00 in a research report on Monday, May 2nd. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $65.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 17th. Barclays increased their price objective on shares of Bristol-Myers Squibb from $66.00 to $68.00 in a research note on Monday, May 2nd. StockNews.com began coverage on shares of Bristol-Myers Squibb in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Finally, Morgan Stanley dropped their price objective on shares of Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $71.89.

Bristol-Myers Squibb Profile (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

See Also

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.